Company / PP&E (Net)
Oruka Therapeutics, Inc. PP&E (Net) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$162.0K
FY2024
5-year range
$10.0K / $162.0K
FY2020-FY2024
Trend
+1520.0%
vs FY2023
Sector context
#182 of 193
Health Care
What the data says
PP&E (Net) changed +1520% YoY in FY2024, a notable deviation from the 9-year average annual change of +183%.
Based on SEC 10-K filings.
$162,000 in FY2024 with a 5-year CAGR of +74.5%.
Improved from $25,000 to $162,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +50.0%
- 5-Year CAGR
- +74.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 193This company $162.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +74.5%, indicating consistent growth.
- In FY2024, pp&e (net) increased 1520.0% year-over-year.
- Ranks #182 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $162.0K | +1520.0% |
| FY2023 | $10.0K | -60.0% |
| FY2022 | $25.0K | -47.9% |
| FY2021 | $48.0K | +128.6% |
| FY2020 | $21.0K | +110.0% |
| FY2019 | $10.0K | -58.3% |
| FY2018 | $24.0K | -42.9% |
| FY2017 | $42.0K | -36.4% |
| FY2016 | $66.0K | +135.7% |
| FY2015 | $28.0K | -22.2% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026